Skip to main content
. 2021 Nov 18;126(5):744–753. doi: 10.1038/s41416-021-01629-x

Fig. 4. ASP2453 shows potent anti-tumour activity in multiple human cancer xenograft models.

Fig. 4

a Anti-tumour activity of ASP2453 in a subcutaneous KRAS G12C-mutated MIA PaCa-2 xenograft model (n = 5 mice per group, mean ± SEM). *P < 0.05, ****P < 0.0001, Dunnett’s multiple comparison test compared with vehicle. b Anti-tumour activity of ASP2453 in a subcutaneous KRAS G12C-mutated LXFA592 PDX xenograft model (vehicle or 30 mg/kg-treated group: n = 8 mice per group, 10 mg/kg-treated group: n = 7 mice per group, mean ± SEM). ***P < 0.001, Dunnett’s multiple comparison test compared with vehicle. c Anti-tumour activity of ASP2453 in a subcutaneous KRAS WT A375 xenograft model (n = 5 mice per group, mean ± SEM). d Bioluminescence imaging of mice orthotopically inoculated with NCI-H1373-Luc cells administered ASP2453. Day 0: day of randomisation. Representative images of 10 mice from each group are shown. e Survival of mice orthotopically inoculated with NCI-H1373-Luc cells administered ASP2453 (n = 10 mice per group). **P < 0.01, ****P < 0.0001, two-sided Mantel–Cox test compared with vehicle.